High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma
Abstract Conventional chemotherapeutic agents are nonselective, often resulting in severe side effects and the development of resistance. Therefore, new molecular-targeted therapies are urgently needed to be integrated into existing treatment regimens. Here, we performed a high-throughput compound s...
Guardado en:
Autores principales: | Katja Tuomainen, Aini Hyytiäinen, Ahmed Al-Samadi, Philipp Ianevski, Aleksandr Ianevski, Swapnil Potdar, Laura Turunen, Jani Saarela, Sergey Kuznetsov, Wafa Wahbi, Maija Risteli, Antti Mäkitie, Outi Monni, Tuula Salo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/94f7ab850a6441f089e9e315a0b84667 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic
por: Ana C. Henriques, et al.
Publicado: (2021) -
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
por: Yonghan He, et al.
Publicado: (2020) -
Endocrine Disorders and Genital Infections Impair Gynecological Health in APECED (APS-1)
por: Viivi Saari, et al.
Publicado: (2021) -
Assessing survival rate of HPV-positive and HPV-negative cervical cancer patients
por: M. K. Ibragimova, et al.
Publicado: (2019) -
Perceptions of HPV vaccination and pharmacist-physician collaboration models to improve HPV vaccination rates
por: Benjamin S. Teeter, et al.
Publicado: (2021)